- Conditions
- Migraine
- Interventions
- Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]
- Drug
- Lead sponsor
- David True
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- City of Saint Peters, Missouri • Springfield, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
- Interventions
- Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Migraine, Menstrual Migraine, Menstrually Related Migraine
- Interventions
- Fremanezumab, Placebo
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chestnut Hill, Massachusetts
- Conditions
- Migraine
- Interventions
- Fremanezumab-Vfrm, BLAfit®, Saline
- Drug · Device · Other
- Lead sponsor
- Manhattan Beach Orthodontics
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Manhattan Beach, California
- Conditions
- Migraine
- Interventions
- Eptinezumab, Erenumab, Onabotulinumtoxin-A, Fremanezumab, Galcanezumab
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Stamford, Connecticut • Palmetto Bay, Florida + 7 more
- Conditions
- Cranial Nerve Injury, Oropharyngeal Cancer
- Interventions
- Prednisone, Ajovy, Manual Therapy, IOPI device
- Drug · Other · Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Migraine, Headache
- Interventions
- Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)
- Drug
- Lead sponsor
- Chicago Headache Center & Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Migraine Disorders, Sleep Disorder
- Interventions
- Fremanezumab Prefilled Syringe [Ajovy]
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts